SCHEMBL1099192

SCHEMBL1099192

CCCCN(c1cc2ccccc2s1)S(=O)(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 5/20 0.59
PTGES O14684 4/20 0.54
L3MBTL1 Q9Y468 1/20 0.48
ESR1 P03372 1/20 0.48
CA12 O43570 1/20 0.47
CA2 P00918 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CA9 Q16790 1/20 0.47
SLC22A6 Q4U2R8 1/20 0.47
SLC22A8 Q8TCC7 1/20 0.47
ABCC2 Q92887 1/20 0.47
SLC22A12 Q96S37 1/20 0.47
UGT1A7 Q9HAW7 1/20 0.47
SLC22A11 Q9NSA0 1/20 0.47
GAA P10253 1/20 0.46
TRPM8 Q7Z2W7 7/20 0.44
NR1I2 O75469 1/20 0.42
MCL1 Q07820 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098865 0.90 TDP1 (0.51) ALOX5PTGESL3MBTL1ESR1RAB9A
SCHEMBL1099255 0.89 L3MBTL1 (0.62) ALOX5PTGESL3MBTL1ESR1CA12
SCHEMBL1100059 0.86 ALOX5 (0.43) ALOX5PTGESTRPM8
SCHEMBL1107245 0.85 ALOX5 (0.43) ALOX5PTGESL3MBTL1ESR1RAB9A
SCHEMBL1107236 0.85 ESR1 (0.45) ALOX5PTGESL3MBTL1ESR1GAA
SCHEMBL1099696 0.84 ESR1 (0.47) ALOX5PTGESL3MBTL1ESR1GAA
SCHEMBL1099016 0.84 TRPM8 (0.44) ALOX5PTGESESR1TRPM8
SCHEMBL1107247 0.83 ALOX5 (0.42) ALOX5PTGESL3MBTL1ESR1GAA
SCHEMBL1107237 0.83 ESR1 (0.43) ALOX5L3MBTL1ESR1GAANR1I2
SCHEMBL1100219 0.80 CNR2 (0.44) ALOX5ESR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 ALOX5 2892/4885PTGES 309/4885L3MBTL1 3261/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 ALOX5 2892/4885PTGES 309/4885L3MBTL1 3261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.